# Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer

> **NCT05643677** · PHASE2 · UNKNOWN · sponsor: **Fujian Medical University** · enrollment: 47 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Fruquintinib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT05643677
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12
- **Primary completion:** 2024-11
- **Final completion:** 2025-11
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2022-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05643677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05643677, "Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05643677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*